ArticleJournal of neurology2025
Natural history of facioscapulohumeral muscular dystrophy evaluated by multiparametric quantitative MRI: a prospective cohort study.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Standardizing quantitative muscle MRI: an inter-vendor evaluation in healthy adults.Magma (New York, N.Y.) · 2026Article
- Whole-Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies.Annals of clinical and translational neurology · 2026Article
- Immunohistological and electron microscopy profile of unique TIRM-MRI guided muscle biopsies of FSHD patients.Journal of neuromuscular diseases · 2026Article
- RNA cargo profiling of muscle extracellular vesicles identifies candidate biomarkers of disease activity and muscle degeneration in FSHD.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundFacioscapulohumeral muscular dystrophy (FSHD) is a genetic disorder characterized by progressive skeletal muscle wasting. Longitudinal muscle magnetic resonance imaging (MRI) studies demonstrated that the risk of developing irreversible fatty replacement is higher in muscles showing edematous lesions. The quantification of this phenomenon is an understudied topic in FSHD and intramuscular water content can also represent a potential biomarker sensitive to the effect of investigational drugs. We applied a multiparametric quantitative muscle MRI protocol to assess disease progression quantifying fatty replacement and muscle edema over 2 years, using fat fraction (FF) and water-T2 (wT2) metrics.
methodsThirty FSHD patients with at least one muscle showing signs of edema on conventional MRI were enrolled. FF and wT2 maps were assessed in 12 thigh and 6 leg muscles for each side, and a linear mixed model was employed to explore their variations over time. The measurements were acquired at baseline, 12, and 24 months. Quantitative MRI parameters were also correlated with clinical scales and functional assessments collected at baseline.
resultsThe average yearly increase in FF was 2 ± 0.6% at thigh level and 1.9 ± 0.7% at leg level. No significant longitudinal changes in wT2 were observed. Muscles with intermediate FF (15-30%) at baseline and those with baseline wT2 values above 41 ms showed the highest increase in fat replacement. Both FF and wT2 showed significant correlations with clinical scales and functional assessments.
conclusionsOur longitudinal study identified muscles and compartments more likely to show FF increase in FSHD subjects. Multiparametric quantitative MRI metrics should be incorporated into clinical trial frameworks to explore their potential in detecting early therapeutic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.